Oncogene:USP14调节的雄激素受体去泛素化的抑制能够促使雄激素受体阳性乳腺癌细胞的生长停滞和凋亡诱导

2018-02-05 AlexYang MedSci原创

众所周知,雄激素受体(AR)对前列腺癌的发展和恶化非常关键。另外,已经有研究报道在多于60%的乳腺癌肿瘤中AR表现为表达,这也促使了雌激素受体阴性(ER-)/AR阳性(AR+)乳腺癌细胞的生长。因此,AR也许是AR+/ER-乳腺癌病人的一个潜在的治疗靶标。之前,研究人员报道了在前列腺癌细胞中,蛋白酶体相关的去泛素化酶-泛素特异性蛋白酶14(USP14)能够通过移除泛素链维持AR蛋白水平。最近,有研

众所周知,雄激素受体(AR)对前列腺癌的发展和恶化非常关键。另外,已经有研究报道在多于60%的乳腺癌肿瘤中AR表现为表达,这也促使了雌激素受体阴性(ER-)/AR阳性(AR+)乳腺癌细胞的生长。因此,AR也许是AR+/ER-乳腺癌病人的一个潜在的治疗靶标。

之前,研究人员报道了在前列腺癌细胞中,蛋白酶体相关的去泛素化酶-泛素特异性蛋白酶14(USP14)能够通过移除泛素链维持AR蛋白水平。最近,有研究人员研究了USP14-AR蛋白的互作和在USP14减少或者受抑制情况下,乳腺癌细胞的增殖情况。并且,他们的结果支持了以USP14为靶标是一种治疗AR相关乳腺癌新策略的结论。研究人员发现,USP14的抑制可以加速K48泛素化和蛋白酶体调控的AR蛋白的降解。另外,在AR相关乳腺癌细胞中,USP14的遗传和药物抑制都能够显著的抑制细胞增殖,机理是阻断G0/G1到S期的转换和诱导细胞凋亡。更多的是,AR过表达能够抑制USP14抑制诱导的事件,表明了USP14调控的AR去泛素化对乳腺癌的生长是非常重要的,并且USP14抑制作用是治疗AR阳性乳腺癌的一个可能的治疗策略。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048973, encodeId=d25b20489e38c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 20 12:09:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980846, encodeId=237e198084610, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Nov 29 04:09:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252466, encodeId=06301252466de, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350529, encodeId=c0801350529d4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558104, encodeId=8e501558104ff, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]
    2018-04-20 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048973, encodeId=d25b20489e38c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 20 12:09:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980846, encodeId=237e198084610, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Nov 29 04:09:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252466, encodeId=06301252466de, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350529, encodeId=c0801350529d4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558104, encodeId=8e501558104ff, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048973, encodeId=d25b20489e38c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 20 12:09:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980846, encodeId=237e198084610, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Nov 29 04:09:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252466, encodeId=06301252466de, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350529, encodeId=c0801350529d4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558104, encodeId=8e501558104ff, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]
    2018-02-07 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048973, encodeId=d25b20489e38c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 20 12:09:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980846, encodeId=237e198084610, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Nov 29 04:09:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252466, encodeId=06301252466de, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350529, encodeId=c0801350529d4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558104, encodeId=8e501558104ff, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048973, encodeId=d25b20489e38c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 20 12:09:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980846, encodeId=237e198084610, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Nov 29 04:09:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252466, encodeId=06301252466de, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350529, encodeId=c0801350529d4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558104, encodeId=8e501558104ff, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 07 12:09:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]

相关资讯

Stem cells:沉默Aldefluor+ 乳腺CSCs的TAP1的表达有助于肿瘤细胞免疫逃逸

逃逸细胞免疫细胞的检测和破坏是肿瘤发生和进展的关键。癌干细胞(CSCs)在肿瘤发生中的重要作用已得到明确,但其逃逸免疫检测和靶向的能力尚未完全了解。在探究乳腺CSCs逃逸免疫检测的能力的过程中,Mohammad Sultan等人基于醛脱氢酶活性增强在一个自发性小鼠乳腺瘤中鉴别出一钟高度致瘤的分子。研究人员在免疫强化和免疫缺陷的小鼠中进行肿瘤生长研究。在免疫强化的小鼠中,自发性乳腺肿瘤的生长受到抑制

Nature:乳腺癌治愈后如何降低复发风险?

接受乳腺癌治疗之后,乳腺癌患者的生活也逐渐走向正常化,通常情况下我们认为治疗的第5年是一个关键节点,如果完全缓解后5年达到无病生存,通常就认为癌症被治愈了。但是,近来有研究发现,休眠的癌细胞可能存在于一个可支持其生存的微环境,在治疗5年后癌细胞依旧可能被唤醒并发生转移。

顺铂脂质体治疗乳腺癌获积极临床结果

1 月 31 日,位于丹麦的 Medical Prognosis Institute(MPI)子公司 Oncology Venture 公布了第二份关于药物 LiPlaCis 用于难治型转移性乳腺癌治疗的临床 2 期试验部分(属于临床 1 / 2 期研究)的中期报告。

NSABP B-47证实HER2低表达乳腺癌未从曲妥珠单抗辅助治疗获益

HER2扩增或过表达(IHC3+)侵袭性乳腺癌辅助性曲妥珠单抗治疗能减少复发并改善生存,NSABP B-31和N9831的回顾性研究认为HER2低表达乳腺癌也可能获益于曲妥珠单抗辅助治疗。事实究竟如何呢?NSABP B-47研究结果证实IHC1+/2+或FISH比率<2.0乳腺癌,标准辅助治疗中加入曲妥珠单抗无获益。

2018 AHA科学声明:心血管疾病和乳腺癌

心血管疾病仍是女性死亡的主要原因,然而,许多人认为乳腺癌对妇女健康的头号威胁。心血管和乳腺癌有好几种重叠的危险因素,例如肥胖和吸烟。此外,当前乳腺癌治疗也对心血管有负面影响。本文主要主要对这些疾病的流行情况进行了全面概述,涉及共同危险因素,治疗的心脏毒性作用以及乳腺癌患者心血管疾病的治疗和预防。

富氧微泡使乳腺癌细胞对放射性疗法更敏感

近日,研究人员公布的一组数据称,经富氧微泡注射后的乳腺癌细胞对放射治疗的敏感性增加了三倍,并显著改善了疾病动物模型的存活。因此这项研究为该技术向乳腺癌治疗的临床转化提供了强有力的支持。